A5047846622- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Pharmaceutical studies and practices
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
Sun Yat-sen University
2025
Sun Yat-sen University Cancer Center
2025
ABSTRACT Mosunetuzumab, a CD20 × CD3 T‐cell‐engaging bispecific antibody, redirects T cells to eliminate malignant B cells. The purpose of YO43555 was assess the pharmacokinetics (PK), safety, tolerability, and efficacy mosunetuzumab as single agent in Chinese patients with relapsed/refractory follicular lymphoma (R/R FL). impact ethnicity/region on PK disposition assessed by non‐compartmental analysis (NCA) well population (popPK) approach. A previously established popPK model for...
7013 Background: Patients (pts) with transplant-ineligible r/r DLBCL have an unmet need, objective response rate (ORR) of around 40%. CD79b, a key component the B-cell receptor and expressed in majority mature malignancies origin, is attractive therapeutic target for DLBCL. We initiated phase 1b/2 study to assess safety efficacy SHR-A1912, novel CD79b-targeted ADC, combination chemotherapy pts or treatment-naive Here, we report findings SHR-A1912 plus R-GemOx regimen cohort. Methods: The...